FGF19 and FGF21: In NASH we trust

OBJECTIVE: FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development. METHODS: We performed a detailed analyses of published preclinical and clinical data to o...

Descripción completa

Detalles Bibliográficos
Autores principales: Talukdar, Saswata, Kharitonenkov, Alexei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085573/
https://www.ncbi.nlm.nih.gov/pubmed/33383173
http://dx.doi.org/10.1016/j.molmet.2020.101152
Descripción
Sumario:OBJECTIVE: FGF19 and FGF21 have shown therapeutic promise since their discovery, attested by the fact there are at least 5 assets that activate the FGFR/KLB pathway and one FGF19 analog in clinical development. METHODS: We performed a detailed analyses of published preclinical and clinical data to offer insights into the mechanism of action, as well as PK/PD and efficacy data of the clinical assets. RESULTS: Scouring the literature, we offer mechanistic insights from preclinical data using rodents and non-human primates and pharmacodynamic data from clinical studies. CONCLUSION: The basic and applied science around endocrine FGFs has evolved exponentially over the years with FGF19 and FGF21 analogs are now entering Phase 3 clinical research.

Ejemplares similares